Crossref
100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States
JACC: Cardiovascular Interventions · 2026-03 · 19 (5) · S14
DOI: 10.1016/j.jcin.2026.01.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-03. Verfasst von Siyu Ma.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ma, S. (2026). 100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States. JACC: Cardiovascular Interventions, 19(5), S14. https://doi.org/10.1016/j.jcin.2026.01.045
Vancouver
Ma S. 100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States. JACC: Cardiovascular Interventions. 2026;19(5):S14. doi:10.1016/j.jcin.2026.01.045
BibTeX
@article{Ma2026,
author = {Ma, Siyu},
title = {100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {5},
pages = {S14},
doi = {10.1016/j.jcin.2026.01.045}
}
EUVIMED